ES2782380T5 - Método de especificación y cultivo de linaje del músculo esquelético escalable - Google Patents
Método de especificación y cultivo de linaje del músculo esquelético escalable Download PDFInfo
- Publication number
- ES2782380T5 ES2782380T5 ES14858383T ES14858383T ES2782380T5 ES 2782380 T5 ES2782380 T5 ES 2782380T5 ES 14858383 T ES14858383 T ES 14858383T ES 14858383 T ES14858383 T ES 14858383T ES 2782380 T5 ES2782380 T5 ES 2782380T5
- Authority
- ES
- Spain
- Prior art keywords
- cell line
- myogenic
- self
- differentiation
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 50
- 210000002027 skeletal muscle Anatomy 0.000 title description 19
- 210000004027 cell Anatomy 0.000 claims description 143
- 230000001114 myogenic effect Effects 0.000 claims description 49
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 39
- 229960003722 doxycycline Drugs 0.000 claims description 33
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 33
- 108091023040 Transcription factor Proteins 0.000 claims description 28
- 230000006698 induction Effects 0.000 claims description 28
- 102000040945 Transcription factor Human genes 0.000 claims description 27
- 230000001939 inductive effect Effects 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 17
- 210000000107 myocyte Anatomy 0.000 claims description 17
- 241000894007 species Species 0.000 claims description 17
- 101000958865 Homo sapiens Myogenic factor 5 Proteins 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 claims description 15
- 102100035077 Myoblast determination protein 1 Human genes 0.000 claims description 15
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 15
- 230000001973 epigenetic effect Effects 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 15
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 13
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 13
- 102100032970 Myogenin Human genes 0.000 claims description 13
- 244000144972 livestock Species 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 230000004070 myogenic differentiation Effects 0.000 claims description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 9
- 210000001087 myotubule Anatomy 0.000 claims description 9
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims description 7
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims description 7
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 7
- 235000013622 meat product Nutrition 0.000 claims description 7
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 6
- -1 BIO Chemical compound 0.000 claims description 6
- 108010077544 Chromatin Proteins 0.000 claims description 6
- 229960002756 azacitidine Drugs 0.000 claims description 6
- 210000003483 chromatin Anatomy 0.000 claims description 6
- 235000012631 food intake Nutrition 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 230000007067 DNA methylation Effects 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 108010033040 Histones Proteins 0.000 claims description 3
- 102000006947 Histones Human genes 0.000 claims description 3
- 101000958866 Homo sapiens Myogenic factor 6 Proteins 0.000 claims description 3
- 101000601661 Homo sapiens Paired box protein Pax-7 Proteins 0.000 claims description 3
- 102100038379 Myogenic factor 6 Human genes 0.000 claims description 3
- 102100037503 Paired box protein Pax-7 Human genes 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000010362 genome editing Methods 0.000 claims description 3
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 claims description 2
- DXYYSGDWQCSKKO-UHFFFAOYSA-N 2-methylbenzothiazole Chemical compound C1=CC=C2SC(C)=NC2=C1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 claims description 2
- MDYDGUOQFUQOGE-UHFFFAOYSA-N 2-methylpropanethioic acid S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl] ester Chemical compound S1C(NC(=O)CCCCCCSC(=O)C(C)C)=NC(C=2C=CC=CC=2)=C1 MDYDGUOQFUQOGE-UHFFFAOYSA-N 0.000 claims description 2
- JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 claims description 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 2
- ZKJAZFUFPPSFCO-UHFFFAOYSA-N 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione Chemical compound CC=1NC2=CC=CC=C2C=1C=1C(=O)N(C)C(=O)C=1NCCC1=CC=C(F)C=C1 ZKJAZFUFPPSFCO-UHFFFAOYSA-N 0.000 claims description 2
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 2
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 claims description 2
- RZWRYPGAUIOOMK-UHFFFAOYSA-N 5-nitroso-8-quinolinol Chemical compound C1=CN=C2C(O)=CC=C(N=O)C2=C1 RZWRYPGAUIOOMK-UHFFFAOYSA-N 0.000 claims description 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 2
- VUWMSJQZENJPHO-UHFFFAOYSA-N 7-oxo-7-(n-phenylanilino)heptanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)CCCCCC(=O)O)C1=CC=CC=C1 VUWMSJQZENJPHO-UHFFFAOYSA-N 0.000 claims description 2
- 241001550224 Apha Species 0.000 claims description 2
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 claims description 2
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 108010028143 Dioxygenases Proteins 0.000 claims description 2
- 102000016680 Dioxygenases Human genes 0.000 claims description 2
- 108010074870 Histone Demethylases Proteins 0.000 claims description 2
- 102000008157 Histone Demethylases Human genes 0.000 claims description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 claims description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 claims description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 2
- 102000003964 Histone deacetylase Human genes 0.000 claims description 2
- 108090000353 Histone deacetylase Proteins 0.000 claims description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 2
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 2
- KPNNXHVGOKRBEF-UHFFFAOYSA-N N-hydroxy-7-(2-naphthalenylthio)heptanamide Chemical compound C1=CC=CC2=CC(SCCCCCCC(=O)NO)=CC=C21 KPNNXHVGOKRBEF-UHFFFAOYSA-N 0.000 claims description 2
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 2
- 229950008805 abexinostat Drugs 0.000 claims description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 2
- 229960003094 belinostat Drugs 0.000 claims description 2
- HQSSEGBEYORUBY-WPWMEQJKSA-N chembl597845 Chemical compound C=1C=CC(\N=C\C=2C3=CC=CC=C3C=CC=2O)=CC=1NC(=O)C(C)C1=CC=CC=C1 HQSSEGBEYORUBY-WPWMEQJKSA-N 0.000 claims description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 claims description 2
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 claims description 2
- 229960005184 panobinostat Drugs 0.000 claims description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 2
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 claims description 2
- 229950005284 tideglusib Drugs 0.000 claims description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
- GOVYBPLHWIEHEJ-UHFFFAOYSA-N tubastatin A Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 GOVYBPLHWIEHEJ-UHFFFAOYSA-N 0.000 claims description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- 101000589002 Homo sapiens Myogenin Proteins 0.000 claims 1
- 102000055027 Protein Methyltransferases Human genes 0.000 claims 1
- 108700040121 Protein Methyltransferases Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 claims 1
- 230000004069 differentiation Effects 0.000 description 47
- 239000002609 medium Substances 0.000 description 44
- 230000011712 cell development Effects 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 18
- 238000001262 western blot Methods 0.000 description 18
- 235000013372 meat Nutrition 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 14
- 108010056785 Myogenin Proteins 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 230000004913 activation Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 230000005283 ground state Effects 0.000 description 11
- 230000030833 cell death Effects 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 108010082117 matrigel Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000007704 transition Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002242 embryoid body Anatomy 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 241000272517 Anseriformes Species 0.000 description 6
- 102100029855 Caspase-3 Human genes 0.000 description 6
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 6
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 6
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 6
- 108010085895 Laminin Proteins 0.000 description 6
- 102000007547 Laminin Human genes 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 210000003716 mesoderm Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102100036912 Desmin Human genes 0.000 description 5
- 108010044052 Desmin Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 102000013814 Wnt Human genes 0.000 description 5
- 108050003627 Wnt Proteins 0.000 description 5
- 210000005045 desmin Anatomy 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 101150063416 add gene Proteins 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 3
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229930189065 blasticidin Natural products 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000022379 skeletal muscle tissue development Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000030939 Bubalus bubalis Species 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000272496 Galliformes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 241000283986 Lepus Species 0.000 description 2
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 2
- 101710111894 Methyl-CpG-binding domain protein 3 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000025164 anoikis Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 238000003352 cell adhesion assay Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001983 electron spin resonance imaging Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 210000003365 myofibril Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 101000582994 Homo sapiens Myelin regulatory factor Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 101150013833 MYOD1 gene Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102100030372 Myelin regulatory factor Human genes 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical group C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102100024837 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Human genes 0.000 description 1
- 101710188227 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000010868 animal carcass Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229950011479 hyclate Drugs 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361962068P | 2013-10-30 | 2013-10-30 | |
| PCT/US2014/063250 WO2015066377A1 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2782380T3 ES2782380T3 (es) | 2020-09-14 |
| ES2782380T5 true ES2782380T5 (es) | 2023-05-08 |
Family
ID=53005145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14858383T Active ES2782380T5 (es) | 2013-10-30 | 2014-10-30 | Método de especificación y cultivo de linaje del músculo esquelético escalable |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160251625A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3071040B2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6728049B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111154726A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014342180B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016009803B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2928726A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2782380T5 (cg-RX-API-DMAC7.html) |
| IL (2) | IL296889A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015066377A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015066377A1 (en) | 2013-10-30 | 2015-05-07 | The Curators Of The University Of Missouri | Method for scalable skeletal muscle lineage specification and cultivation |
| US11318167B2 (en) | 2015-12-11 | 2022-05-03 | The Johns Hopkins University | Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy |
| MX2018008733A (es) * | 2016-01-14 | 2019-01-28 | Memphis Meats Inc | Metodos para extender la capacidad replicativa de las celulas somaticas durante un proceso de cultivo ex vivo. |
| CN109714962A (zh) | 2016-07-11 | 2019-05-03 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 用于在体外培养细胞的系统和方法 |
| WO2018208628A1 (en) | 2017-05-06 | 2018-11-15 | Memphis Meats, Inc. | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure |
| CA3066060A1 (en) * | 2017-06-07 | 2018-12-13 | Wild Type, Inc. | Ex vivo meat production |
| WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION |
| CN111108188A (zh) | 2017-07-15 | 2020-05-05 | 阿利夫农场公司 | 培养肉组合物 |
| GB2573327B (en) * | 2018-05-03 | 2021-05-12 | Mosa Meat Bv | Apparatus and process for production of tissue from cells |
| US12478571B2 (en) | 2018-12-17 | 2025-11-25 | Pontis Biologics, Inc. | Enzyme based compositions and methods for removing dental calculi |
| BR112021022432A2 (pt) | 2019-05-14 | 2021-12-28 | Aleph Farms Ltd | Agregados de células pluripotentes e uso dos mesmos |
| CA3141870C (en) | 2019-05-28 | 2023-08-01 | Upside Foods, Inc. | Apparatuses and methods for preparing a comestible meat product |
| CA3160109C (en) | 2019-11-20 | 2023-07-04 | Upside Foods, Inc. | Apparatuses and systems for preparing a meat product |
| WO2021111196A1 (en) | 2019-12-02 | 2021-06-10 | Avant Meats Company Limited | Methods of meat production by in vitro cell cultivation |
| US20210235733A1 (en) | 2020-02-04 | 2021-08-05 | Memphis Meats, Inc. | Characteristics of meat products |
| CA3179816A1 (en) | 2020-06-05 | 2021-12-09 | Kalle Lukyan JOHNSON | Nutrient media for the production of slaughter-free meat |
| GB202008821D0 (en) * | 2020-06-10 | 2020-07-22 | Highersteaks Ltd | Systems and methods for cell conversion |
| US12252681B2 (en) | 2020-08-18 | 2025-03-18 | Upside Foods, Inc. | Systems, devices, and methods for sterilizing bioreactors and culture media |
| US20220195368A1 (en) * | 2020-12-21 | 2022-06-23 | Upside Foods, Inc. | Fluid conduit with radial expansion of fluid flow |
| US11912967B2 (en) * | 2020-12-22 | 2024-02-27 | Upside Foods, Inc. | Systems and methods for cultivating tissue on porous substrates |
| EP4281543A1 (en) * | 2021-01-22 | 2023-11-29 | Uncommon Bio Limited | Products for cell conversion |
| WO2022192429A1 (en) | 2021-03-10 | 2022-09-15 | Terasaki Insutitute For Biomedical Innovation | Constructs comprising fibrin or other blood products for meat cultivation and other applications |
| GB2622959A (en) | 2021-04-07 | 2024-04-03 | Upside Foods Inc | Generation of cell-based products for consumption that comprise proteins derived from exotic, endangered, and extinct species |
| IL307711B2 (en) | 2021-04-28 | 2025-05-01 | Upside Foods Inc | Creating cell-based products for human consumption |
| IL308274A (en) | 2021-05-06 | 2024-01-01 | Yeda res & development co ltd | A method for creating hypertrophic muscle fibers to create industrial meat |
| EP4346395A4 (en) * | 2021-05-28 | 2025-04-23 | ABS Global, Inc. | In vitro breeding systems and methods in livestock |
| JP2024523133A (ja) | 2021-06-11 | 2024-06-28 | アップサイド フーズ， インコーポレイテッド | 乾燥細胞粉末を含む細胞ベースの肉製品、及びそのような製品の製造方法 |
| JP2024522573A (ja) | 2021-06-16 | 2024-06-21 | アップサイド フーズ， インコーポレイテッド | 細胞ベースの肉の成長のための植物脂肪ベースの足場と当該製品の作成方法 |
| EP4367219A1 (en) | 2021-07-09 | 2024-05-15 | Suprême | Foodstuffs comprising cells differentiated from engineered oligopotent stem cells |
| WO2023069991A1 (en) | 2021-10-19 | 2023-04-27 | Eat Scifi Inc. | Plant base/animal cell hybrid meat substitute |
| WO2023122688A1 (en) * | 2021-12-23 | 2023-06-29 | Upside Foods, Inc. | Scaling up myogenic tissue: late passage myogenicity |
| EP4292440A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Suspension based chicken product formulation |
| EP4293109A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
| US11981884B2 (en) | 2022-10-17 | 2024-05-14 | Upside Foods, Inc. | Pipe-based bioreactors for producing comestible meat products and methods of using the same |
| WO2025011578A1 (zh) * | 2023-07-10 | 2025-01-16 | 中国农业大学 | 一种猪多能干细胞的肌源性分化方法及其用于细胞培养肉制备 |
| EP4497814A1 (de) | 2023-07-28 | 2025-01-29 | Green Elephant Biotech GmbH | Vorrichtung zur vermehrung von differenzierten und undifferenzierten zellen und verwendung der vorrichtung für die herstellung von kultivierten lebensmitteln |
| WO2025049891A1 (en) | 2023-09-01 | 2025-03-06 | Upside Foods, Inc. | Transposon system and methods of using the same |
| US20250120418A1 (en) * | 2023-10-12 | 2025-04-17 | Btl Healthcare Technologies A.S. | Pet food, methods and devices for producing pet food |
| WO2025141211A1 (en) * | 2023-12-29 | 2025-07-03 | Meatable B.V. | Cells for forward programming |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510254A (en) | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
| IE904639A1 (en) * | 1989-12-21 | 1991-07-17 | Univ Georgia | Bovine myogenic factor gene |
| US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| WO1999031222A1 (en) | 1997-12-18 | 1999-06-24 | Willem Frederik Van Eelen | Industrial scale production of meat from in vitro cell cultures |
| AU743808B2 (en) | 1998-02-27 | 2002-02-07 | Purdue Research Foundation | Submucosa gel compositions |
| US6537782B1 (en) | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| US6835390B1 (en) | 2000-11-17 | 2004-12-28 | Jon Vein | Method for producing tissue engineered meat for consumption |
| EP1639097B1 (en) * | 2003-06-25 | 2013-08-07 | Ottawa Health Research Institute | Methods and compositions for modulating stem cell growth and differentiation |
| DE102004017484B4 (de) | 2004-04-08 | 2006-07-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung einer biologischen Materialzusammensetzung tierischen Ursprungs |
| US20060121006A1 (en) | 2004-09-10 | 2006-06-08 | Chancellor Michael B | Production of nutritional and therapeutic products from cultured animal cells |
| EA018218B1 (ru) | 2004-09-17 | 2013-06-28 | Джон Вейн | Способ получения мясных продуктов питания нечеловеческого происхождения in vitro и продукты, полученные этим способом |
| CN101291596A (zh) * | 2005-11-02 | 2008-10-22 | 雀巢技术公司 | 减少雄性哺乳动物体脂肪积累的异黄酮组合物，以及其使用方法 |
| WO2007100695A2 (en) * | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Metabolic regulators and uses thereof |
| DE102007029699B4 (de) | 2007-06-27 | 2010-12-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Isolierte proliferierende Zellen mit Stammzelleigenschaften aus adultem Gewebe von wechselwarmen Wirbeltieren, stabile Zellkulturen davon und Verfahren zu deren Herstellung |
| CN101624570B (zh) | 2008-07-07 | 2011-04-13 | 刘志军 | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 |
| US20110301249A1 (en) | 2008-12-12 | 2011-12-08 | Kedar Challakere | Stem cell enhanced protein products and uses therof |
| US20110091604A1 (en) | 2009-10-21 | 2011-04-21 | Seth Adrian Miller | Synthetic meat |
| WO2012034101A2 (en) | 2010-09-09 | 2012-03-15 | The Regents Of The University Of California | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them |
| WO2012170995A2 (en) * | 2011-06-10 | 2012-12-13 | University Of Georgia Research Foundation, Inc. | Avian induced pluripotent stem cells and their use |
| CA2780087A1 (en) | 2011-06-14 | 2012-12-14 | Jacques P. Tremblay | Myogenic differentiation of stem cells and uses thereof |
| US8883503B2 (en) | 2011-06-23 | 2014-11-11 | Indian Institute Of Technology Kanpur | Hydrogel scaffolds for tissue engineering |
| AU2012281069B2 (en) | 2011-07-12 | 2016-10-13 | Impossible Foods Inc. | Methods and compositions for consumables |
| US10039306B2 (en) | 2012-03-16 | 2018-08-07 | Impossible Foods Inc. | Methods and compositions for consumables |
| ES2685638T3 (es) | 2011-07-26 | 2018-10-10 | The Curators Of The University Of Missouri | Carne comestible producida artificialmente |
| CA2792081C (en) * | 2011-10-11 | 2020-10-27 | Bond University Ltd | Layered compositions comprising 3d nanofibre webbing for tissue repair |
| US9862929B2 (en) * | 2011-11-18 | 2018-01-09 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to skeletal muscle cells |
| IN2014DN08481A (cg-RX-API-DMAC7.html) | 2012-03-16 | 2015-05-08 | Impossible Foods Inc | |
| EP2831291B1 (en) | 2012-03-28 | 2019-04-24 | Modern Meadow, Inc. | Engineered leather and methods of manufacture thereof |
| WO2014110540A1 (en) | 2013-01-11 | 2014-07-17 | Maraxi, Inc. | Non-dairy cheese replica comprising a coacervate |
| JP2016514953A (ja) | 2013-02-22 | 2016-05-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | テロメア伸長に関する化合物、組成物、方法及びキット |
| WO2015038988A1 (en) | 2013-09-13 | 2015-03-19 | Modern Meadow, Inc. | Edible and animal-product-free microcarriers for engineered meat |
| WO2015066377A1 (en) | 2013-10-30 | 2015-05-07 | The Curators Of The University Of Missouri | Method for scalable skeletal muscle lineage specification and cultivation |
| US9526267B2 (en) | 2014-04-17 | 2016-12-27 | Savage River, Inc. | Nutrient-dense meat structured protein products |
| US20150296834A1 (en) | 2014-04-17 | 2015-10-22 | Savage River, Inc. dba Beyond Meat, Inc. | Plant based meat structured protein products |
| MX2018000941A (es) | 2015-07-24 | 2019-08-29 | Synthetic Genomics Inc | Ingrediente alimenticio rico en proteinas a partir de biomasa y metodos de produccion. |
| MX2018008733A (es) | 2016-01-14 | 2019-01-28 | Memphis Meats Inc | Metodos para extender la capacidad replicativa de las celulas somaticas durante un proceso de cultivo ex vivo. |
| WO2018208628A1 (en) | 2017-05-06 | 2018-11-15 | Memphis Meats, Inc. | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure |
| WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION |
-
2014
- 2014-10-30 WO PCT/US2014/063250 patent/WO2015066377A1/en not_active Ceased
- 2014-10-30 JP JP2016552246A patent/JP6728049B2/ja active Active
- 2014-10-30 AU AU2014342180A patent/AU2014342180B2/en not_active Ceased
- 2014-10-30 US US15/033,207 patent/US20160251625A1/en not_active Abandoned
- 2014-10-30 CN CN202010084479.7A patent/CN111154726A/zh active Pending
- 2014-10-30 EP EP14858383.4A patent/EP3071040B2/en active Active
- 2014-10-30 CA CA2928726A patent/CA2928726A1/en active Pending
- 2014-10-30 ES ES14858383T patent/ES2782380T5/es active Active
- 2014-10-30 IL IL296889A patent/IL296889A/en unknown
- 2014-10-30 CN CN201480061537.7A patent/CN105899079A/zh not_active Withdrawn
- 2014-10-30 BR BR112016009803-0A patent/BR112016009803B1/pt active IP Right Grant
-
2016
- 2016-04-20 US US15/134,252 patent/US10920196B2/en active Active
- 2016-04-24 IL IL245292A patent/IL245292B2/en unknown
-
2019
- 2019-04-02 AU AU2019202244A patent/AU2019202244B2/en not_active Ceased
-
2020
- 2020-01-17 JP JP2020005873A patent/JP2020089381A/ja active Pending
-
2021
- 2021-02-12 US US17/175,324 patent/US20210171912A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019202244A1 (en) | 2019-04-18 |
| JP6728049B2 (ja) | 2020-07-22 |
| AU2019202244B2 (en) | 2021-09-23 |
| CA2928726A1 (en) | 2015-05-07 |
| US20210171912A1 (en) | 2021-06-10 |
| ES2782380T3 (es) | 2020-09-14 |
| JP2016535601A (ja) | 2016-11-17 |
| BR112016009803A2 (pt) | 2017-12-05 |
| AU2014342180B2 (en) | 2019-01-03 |
| US20160251625A1 (en) | 2016-09-01 |
| IL245292B (en) | 2022-10-01 |
| IL245292B2 (en) | 2023-02-01 |
| WO2015066377A1 (en) | 2015-05-07 |
| EP3071040B1 (en) | 2020-01-01 |
| BR112016009803B1 (pt) | 2022-02-08 |
| EP3071040A1 (en) | 2016-09-28 |
| IL245292A0 (en) | 2016-06-30 |
| CN111154726A (zh) | 2020-05-15 |
| BR112016009803A8 (pt) | 2018-01-30 |
| JP2020089381A (ja) | 2020-06-11 |
| IL296889A (en) | 2022-12-01 |
| US10920196B2 (en) | 2021-02-16 |
| AU2014342180A1 (en) | 2016-05-19 |
| EP3071040A4 (en) | 2017-06-21 |
| EP3071040B2 (en) | 2022-12-28 |
| CN105899079A (zh) | 2016-08-24 |
| US20160227830A1 (en) | 2016-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2782380T5 (es) | Método de especificación y cultivo de linaje del músculo esquelético escalable | |
| JP6131433B2 (ja) | 細胞ｒｎａ発現のための方法 | |
| ES2589122T3 (es) | Estimulación de la ruta de la Wnt en la reprogramación de células somáticas | |
| ES2695550T3 (es) | Método para rejuvenecer células | |
| US20110014164A1 (en) | Efficient induction of pluripotent stem cells using small molecule compounds | |
| Mo et al. | Generation and characterization of bat-induced pluripotent stem cells | |
| Yakhkeshi et al. | In vitro improvement of quail primordial germ cell expansion through activation of TGF‐beta signaling pathway | |
| CN105764334B (zh) | 加强肿瘤生长的方法 | |
| EP2734617B1 (en) | Use of cellular extracts for obtaining pluripotent stem cells | |
| US20210395692A1 (en) | Method For Reducing Differentiation Resistance Of Pluripotent Stem Cells | |
| Lluis et al. | Resetting epigenetic signatures to induce somatic cell reprogramming | |
| HK1229164B (en) | Method for scalable skeletal muscle lineage specification and cultivation | |
| HK1229164A1 (en) | Method for scalable skeletal muscle lineage specification and cultivation | |
| Siddall et al. | Myc-what we have learned from flies | |
| Gu et al. | Hyperthermia suppresses the biological characteristics and migration of chicken primordial germ cells | |
| Almeida | An investigation of cell cycle regulation during in vitro models of diapause | |
| EP2646557B1 (en) | Method for cellular rna expression | |
| Rambow | Investigation of the tumorigenicity of GoST cells derived from miPS cells | |
| FATHIMA | ISOLATION AND CHARACTERIZATION OF MYOSATELLITE CELLS FROM CLARIAS MAGUR (HAMILTON, 1822) | |
| Francis | Induced Pluripotent Stem Cells as an Alternative to Embryonic Stem Cells for the Treatment of Type 1 Diabetes |